Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements.[ Read More ]
The intrinsic value of one SBFM stock under the base case scenario is HIDDEN Compared to the current market price of 2.35 USD, Sunshine Biopharma, Inc. is HIDDEN
Current Assets | 24.9 M |
Cash & Short-Term Investments | 16.3 M |
Receivables | 2.55 M |
Other Current Assets | 6.05 M |
Non-Current Assets | 2.46 M |
Long-Term Investments | 0 |
PP&E | 1.01 M |
Other Non-Current Assets | 1.44 M |
Current Liabilities | 5.55 M |
Accounts Payable | 2.59 M |
Short-Term Debt | 119 K |
Other Current Liabilities | 2.85 M |
Non-Current Liabilities | 588 K |
Long-Term Debt | 539 K |
Other Non-Current Liabilities | 48.7 K |
Revenue | 24.1 M |
Cost Of Revenue | 15.8 M |
Gross Profit | 8.34 M |
Operating Expenses | 13.1 M |
Operating Income | -4.79 M |
Other Expenses | -279 K |
Net Income | -4.51 M |
Net Income | -4.51 M |
Depreciation & Amortization | 149 K |
Capital Expenditures | -788 K |
Stock-Based Compensation | 0 |
Change in Working Capital | -4.42 M |
Others | -94.4 K |
Free Cash Flow | -9.56 M |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
8 months ago
Mar 04, 2024
|
Bought 10 K USD
|
Slilaty Steve N.
Chief Executive Officer |
+ 100000
|
0.1 USD |
9 months ago
Feb 08, 2024
|
Bought 2 K USD
|
Slilaty Steve N.
Chief Executive Officer |
+ 20000
|
0.1 USD |
1 year ago
Nov 30, 2022
|
Bought 22.9 K USD
|
Sebaaly Camille
CFO/Secretary |
+ 30000
|
0.7635 USD |
2 years ago
Jun 03, 2022
|
Bought 30.5 K USD
|
Sebaaly Camille
CFO/Secretary |
+ 25000
|
1.22 USD |
8 years ago
Apr 12, 2016
|
Bought 50 K USD
|
Slilaty Steve N.
Chief Executive Officer |
+ 253082
|
0.1976 USD |
9 years ago
May 27, 2015
|
Bought 50 K USD
|
Slilaty Steve N.
Chief Executive Officer |
+ 500000
|
0.1 USD |
12 years ago
Sep 04, 2012
|
Sell 130 K USD
|
Slilaty Steve N.
Chief Executive Officer |
- 2591500
|
0.05 USD |